Med Life SA · BVB:M
Med Life SA — FY2019 Earnings Presentation
15 slides from Med Life SA's earnings presentation, Feb 21, 2020
Slide 1: Year-end 2019 Preliminary Results
Year-end 2019 Preliminary Results Conference call presentation 21 February, 2020
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • Main events Q4 / 2019 Highlights 2019 • Key financial data AGENDA • Consolidated Statement of Financial Position Financial overview 2 • Consolidated Statement of Profit and Loss • Consolidated Statement of Cash Flow • OPEX evolution and Operational KPIs Q&A Session 3 3/
Slide 4: Highlights 2019
Highlights 2019 • Main events Q4 / 2019 • Key financial data 1 4/
Slide 5: Main events Q4 / 2019
Main events Q4 / 2019 Completion of Lotus Hospital acquisition (100% shareholding package; December 2019) Completion of Micromedica Group acquisition (100% shareholding package; December 2019) Acquisition of Onco Card Hospital in Brasov (100% shareholding package; December 2019). Company recorded a
Slide 6: Key financial data
Key financial data Historic strong revenue growth of approx. 25% Y-on-Y for the past 3 years In 2019 Pro-forma Sales increased by 24.5%, to 989.5m RON, organic growth of 14.9% Pro-forma EBITDA increased by 74.7% to 166.6mRON, a margin expansion of 4.8pp to 16.8% (from 12.0%) (fig.1) or – before IFRS
Slide 7: Key financial data contd.
Key financial data contd. Sales and EBITDA margin development (fig.3) 1,000,000,000 989,475,024 989,475,024 18.0% 900,000,000 794,562,861 17.0% 16.8% 800,000,000 16.0% 700,000,000 623,219,949 600,000,000 15.0% 502,986,790 500,000,000 14.0% 400,000,000 13.1% 13.0% 300,000,000 12.5% 12.0% 12.0% 200,00
Slide 8: Key financial data contd.
Key financial data contd. Split of Pro-forma EBITDA before IFRS 16: 90.8% Group Owners and 9.2% NCI Pro-forma Net Result increased by 84.6% to 30.9mRON (from 16.7m RON), while Pro-forma Total Comprehensive Income (TCI) by 87.9% to 31.5m RON (from 16.7m RON) or – before IFRS 16 - by 98.3% to 33.2m RO
Slide 9: Financial overview
Financial overview Consolidated Statement of Financial Position Consolidated Stetement of Profit and Loss Consolidated Stetement of Cash Flow OPEX Evolution Operational KPIs 2 9/
Slide 10: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position 10 / 1.Highlights 2019 2. Financial overview 3. Q&A Session
Slide 11: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss 11 / 1.Highlights 2019 2. Financial overview 3. Q&A Session
Slide 12: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow 12 / 1.Highlights 2019 2. Financial overview 3. Q&A Session
Slide 13: OPEX Evolution
OPEX Evolution Note: The Group recorded a 1.4 p.p. decrease of Operating Expenses as % of Sales in FY 2019 as compared to FY 2018: A. 4.4 p.p. decrease of “Rent” as % of Sales, generated by first time adoption of IFRS 16; B. 0.7 p.p. increase of “Third parties and salaries expenses" as % of Sales as
Slide 14: Operational KPIs
Operational KPIs 14 / 1.Highlights 2019 2. Financial overview 3. Q&A Session
Slide 15: Q&A Session Thank you!
Q&A Session Thank you! 3 15 /